A Study of LY2157299 Monohydrate in Healthy Volunteers

Lilly

Status and phase: Completed; Phase 1

Conditions: Healthy Volunteers

Treatments: Drug: [^14C]-LY2157299

Study type: Interventional

Funder types: Industry

Identifiers

NCT01746004

H9H-MC-JBAM (Other Identifier)

14671

Details and patient eligibility

About

This study involves a single dose of 150 milligram (mg) of radiolabeled LY2157299 monohydrate in healthy participants. The study will determine how the body eliminates the radioactivity and LY2157299 monohydrate. Participants must be healthy surgically sterile or postmenopausal females, or sterile males. This study is approximately 8 to 15 days.

Enrollment: 8 estimated patients

Sex: All

Ages: 21 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy surgically sterile females, postmenopausal females, or sterile males
• Body mass index (BMI) of 18.5 to 32.0 kilograms per square meter (kg/m^2)
• Have venous access sufficient to allow for blood sampling

Exclusion criteria

• Have known allergies to LY2157299, related compounds or any components of the formulation
• Have an abnormal blood pressure as determined by the investigator
• Have participated in a [^14C]-study within the last 6 months prior to admission for this study

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 1 patient group

[^14C]-LY2157299

Experimental group

Description:

Single 150 mg oral dose of LY2157299 monohydrate containing 100 micro curies of \[\^14C\] labeled drug

Treatment:

Drug: [^14C]-LY2157299